The present invention relates to compounds of formula I, wherein Y is N or C-R1 R1 is hydrogen or F R1 is hydrogen, halogen or lower alkyl substituted by halogen R2 is hydrogen or lower alkyl or R2 forms together with R4 a 6 membered heterocyclic ring containing -CH2-CH2-O-CH2- or -CH2-CH2-NR-C(O)- R is hydrogen, lower alkyl, phenyl or benzyl R3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions R4 is hydrogen, lower alkyl or lower alkoxyalkyl R4 is hydrogen, lower alkyl, phenyl optionally substituted by halogen or lower alkoxy, or is cycloalkyl, or is pyridinyl optionally substituted by halogen, lower alkyl, lower alkoxy or =0, or is pyrimidinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is 1 -lower alkyl-pyridinyl, or is pyrazinyl, or is pyridazinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is l-methylpyrrolo[2,3-b]pyridine-5-yl, or is 6-imidazo[l,2- b]pyridazin-6-yl or R4 forms together with R4 a 4, 5 or 6 membered heterocyclic ring containing -(CH2)5-, -CH2-CH2-O-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-O-CH2-CH2- or CH2-CH2-CH2-O-CH2 R5 and R5 are hydrogen or lower alkyl or R4 forms together with R5 a saturated 5- membered ring containing -CH2-CH2-CH2- or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinsons disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.La présente invention concerne des composés de formule I, dans laquelle Y est N ou C-R1 R1 est un hydrogène ou F R1 est un hydrogène, un halogène ou un alkyle inférieur substitué par un halogène R2 est un hydrogène ou un alkyle inférieur ou R2 forme avec R4 un cycle hétérocyclique à 6 chaînons contenant -CH2-CH2-O-CH2- ou -CH2-CH2-NR-C(O)- R est un hydrogène, un alkyle infé
